Introduction
============

Lung cancer is the leading cause of death among all types of cancer, both in males and females. Lung cancer is classified into two major classes as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). About 80-85% of all lung cancer cases are NSCLC whereas SCLC forms the remaining fraction [@B1]. Epidemiological studies indicate tobacco smoking and alcohol consumption as one of the main causes of lung cancer but approximately 10% of all cases are never smokers [@B2], [@B3]. In addition to smoking, development and progression of lung cancer are under the influence of genetic, epigenetic and environmental factors [@B4]-[@B7].

Chromosomal aberrations include the loss or gains of partial or whole chromosomal arms on several chromosomes and are a hallmark of cancer cells. Increases in the gene copy numbers due to chromosomal amplifications constitute a common mechanism for oncogene activation. Cytogenetic studies using comparative genomic hybridization (CGH) and fluorescence *in situ* hybridization (FISH) have already associated chromosomal aberrations with non-small cell lung cancer (NSCLC) [@B8], [@B9]. In particular, oncogene activation through increased gene copy numbers resulting in overexpression contributes to the malignant transformation in various solid tumors, including NSCLC.

Amplification of the 11q13 region has been frequently detected in different kinds of human malignancies, including lung cancer [@B10], [@B11]. Concurrent or independent amplification of four core regions have been identified within the 11q13 region. One of the key genes driving the amplification of 11q13 is the cyclin D1 (CCND1) gene [@B12]. *CCND1* is a key regulatory protein that plays an important role in the transition from G1 to the S phase of the cell cycle during cell division. Overexpression of *CCND1* results in increased proliferation and disruption of the normal cell cycle [@B13]. Therefore, *CCND1* is considered an essential regulator of the cell cycle. Deregulation of *CCND1* has also been implicated in the pathogenesis of lung cancer and is associated with poor prognosis [@B14].

Chromosome 11q13 is a gene-dense region and in addition to *CCND1* several other genes have been implicated in its amplification [@B15]. Evidence shows that the *EMSY* gene may be another driver of the 11q13 amplification [@B16]. *EMSY* has been identified as a novel BRCA2-interacting protein that is amplified both in breast and ovarian cancers [@B17]. It has also been reported that the activation or repression function of the BRCA2/EMSY complex may be involved in DNA repair. More recently, Rodriguez *et al.* reported that *EMSY* is overexpressed and co-amplified together with *CCND1* in patients with sporadic breast cancer [@B18]. In our previous study, we also observed co-amplification of *EMSY* and *CCND1* genes in 10 of 82 (12.2%) patients with lung cancer [@B19]. In the literature, most studies have focused on *CCND1* in lung cancer in association with 11q13 amplification. There is no report except our previous study investigating the *EMSY* gene in lung cancer.

Therefore, in this study, considering the contribution of *CCND1* and *EMSY* to the progression of various types of cancer, we investigated the expression levels of both genes in a group of 85 NSCLC tumor samples which have been analyzed for amplification of the 11q13 region.

Methods
=======

Tissue Samples
--------------

85 patients with NSCLC who underwent surgical resection at the Istanbul University Cerrahpasa Medical Faculty, Department of Chest Surgery were included in the study. Tumor and the adjacent healthy lung tissue samples were obtained during surgery and the specimens were confirmed as tumor and normal samples by a pathologist. The patients taken into the study had not received any previous therapy and were admitted to the hospital for the removal of the tumor as the primary treatment. This study was performed according to the Declaration of Helsinki, 1954 and was approved by the Istanbul Faculty of Medicine Ethics Committee (No.292). Signed informed consent was obtained from all patients.

RT-PCR and Real-Time Quantitative RT-PCR
----------------------------------------

Total RNA was isolated from the tumor and normal samples by using the PureLink RNA Mini Kit (Ambion, USA) according to the manufacturer\'s instructions. cDNAs were synthesized from 400 ng of total RNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany). Expression levels of the *CCND1* and *EMSY* genes in the tumors and non-cancerous tissue samples were analyzed by Quantitative Real Time PCR (qRT-PCR) using the LightCycler 480 system (Roche Diagnostics, Mannheim, Germany). PCR reactions were performed in a final volume of 20 μl containing 1×Master Mix, 300 nM gene specific primers (forward: 5\'-TCAGATGACCCAGGAAAAGAG-3\' and reverse: 5\'-CTCTGTCCCCTCATCAGTGC-3\') and 200 nM hydrolysis probe (UPL Probe No.2) for *EMSY* and (forward: 5\'-GCTGTGCATCTACACCGACA-3\' and reverse: 5\'-TTGAGCTTGTTCACCAGGAG-3\') and 200 nM hydrolysis probe (UPL Probe No.17) for *CCND1*which were labeled with fluorescein (FAM) at the 5′-end and with dark quencher at the 3′-end. The Glucose-6-Phosphate Dehydrogenase (*G6PD*) gene was used as the reference to normalize the quantification of mRNA levels. (Primers; forward: 5\'- CATGGTGCTGAGATTTGCCAAC-3\' and reverse: 5\'- TCAACACCTTGACCTTCTCATCAC-3\') probe 5\'-FAM-ATCCGGGACGTGATGCAGAACCACCTAC-VIC/HEX Yellow-3\'). The 2^-ΔΔCt^ method was used to assess the relative mRNA levels [@B20].

Statistical analysis
--------------------

SPSS 21 for Windows (IBM Corp. Released version 2012, IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.) was used for statistical analysis. The association between gene expression levels and clinicopathological characteristics were determined by the χ2 (2-tailed) test. Correlation between the CCND1 and EMSY expression levels was evaluated using the Spearman\'s rho test.

Results
=======

In order to investigate the expression rates of the *EMSY*and *CCND1* genes which are located on the most frequently amplified 11q13 region in human tumors we analyzed the expression levels of the genes in 85 tumors and matched non-cancerous tissue samples from patients with NSCLC by qRT-PCR. Expression of the *EMSY* and *CCND1*genes were increased in 56 (65.8%) and 50 (58.8%) of the patients, respectively. The mean *EMSY* and *CCND1* mRNA expression levels in tumor tissue were 65% and 27% higher than in the corresponding non-cancerous tissue samples, respectively (Table [1](#T1){ref-type="table"}). The difference between the expression levels in the tumors and normal tissue was statistically significant (p\<0.001). On the other hand, we found a strong correlation between the expression rates of both genes (p\<0.001). A total of 65 patients out of 85 showed a concurrent pattern of either up- or down-regulation. An increase in both *CCND1* and *EMSY* expression was observed in 45 (52.9%) patients while 20 (23.5%) tumors had decreased expression of both genes (p\<0.05, r: 0.63) (Table [2](#T2){ref-type="table"}). When we investigated the correlation between the expression levels and clinicopathological characteristics higher *EMSY* and *CCND1* mRNA levels were observed in patients with adenocarcinomas (Table [3](#T3){ref-type="table"}). Of 50 patients with increased *CCND1* expression, 26 (52%) were diagnosed as adenocarcinoma, 17 (34%) as squamous cell carcinoma and 7 (14%) as other pathologies (p=0.024). Similarly, of 56 patients displaying increased *EMSY* expression, 28 (50%) patients had adenocarcinoma, 20 (35.7%) had squamous cell carcinoma and 8 (14.3%) patients had other pathologies (p=0.026). However, no statistically significant correlation was found between the expression levels of both genes and other clinicopathologic characteristics (p≥0.05).

Discussion
==========

The chromosomal 11q13 locus is one of the frequently amplified chromosomal regions in different kinds of human cancers including lung cancer [@B10]. Several studies have provided experimental evidence that the 11q13 amplicon is complex and displays multiple cores potentially harboring distinct drivers [@B21]-[@B23]. While the *CCND1, CTTN (EMS1)*and*GAB2* genes have long been considered as potential drivers of the second core, identification of a novel gene, *EMSY* has suggested that it is the driver of the third core [@B17]. On the other hand, the *CCND1* gene is involved in approximately two thirds of all 11q13 amplicons [@B24]. Despite reports on over-expression of different genes in that region, the most likely tumorigenic driver at this locus is still thought to be *CCND1*, which encodes cyclin D1 [@B25]. Cyclin D1 is a key regulatory protein that plays an important role in the transition from G1 to the S phase of the cell cycle and increases in the *CCND1* copy number have been reported in different kinds of cancer including in breast, esophageal or laryngeal cancers and NSCLC [@B13], [@B25]. In our previous study we also observed *CCND1* amplification in 12.2% of the NSCLC tumor samples [@B19]. However, in our study group we did not observe an association between the increase in copy numbers and expression of the *CCND1* mRNA as reported by Dragoj *et al.* [@B26]. In NSCLC tumors overexpression of *CCND1*was more frequent than copy number variations. Our data indicate that overexpression of the *CCND1* gene can occur independent of gene amplification.

In 2003, *EMSY* has been identified as a BRCA2-binding and inactivating protein by Hughes-Davies *et al.* [@B17]. However, its exact mechanism of action has not been investigated in detail. In recent years more detailed and comprehensive research has aimed to identify the protein partners of EMSY. As a result of these experimental and in silico studies it has been suggested that EMSY may function in DNA damage repair, chromatin remodeling and regulation of transcription [@B17], [@B27]-[@B29]. It has also been reported that *EMSY* was amplified in 13% of sporadic breast cancers, 17% of high grade ovarian cancers and 13% of sporadic pancreatic adenocarcinomas [@B16]-[@B18], [@B30], [@B31]. As to our knowledge, there is no data in the literature except a single study investigating the *EMSY* gene in NSCLC. In this study, Wilkerson *et al.* [@B32] have analyzed amplification of the *EMSY* gene in 10 different cancer cell lines from different anatomical sites. As a result of this study they observed *EMSY*amplification in the NCI-H1395 stage 2 lung cancer cell line. In our previous study we observed a similar frequency of *EMSY*amplification in tumors from patients with NSCLC [@B19]. In some studies *EMSY* amplification has been associated with increased levels of mRNA [@B16], [@B18]. When we investigated *EMSY* expression levels we observed a higher overexpression rate in the tumor samples than the corresponding increase in the copy numbers or amplification. Another interesting point was the concurrent overexpression of *EMSY* with *CCND1*in our study group. It is well known that *CCND1*does not exert its tumorigenic activity by itself [@B26]. This statistically significant association between the overexpression of the *CCND1*and *EMSY* genes in NSCLC indicates that two genes of the chromosome 11q13 amplification region cooperate in lung carcinogenesis. We also detected a significant correlation between overexpression of the *EMSY* and *CCND1* genes and the histologic type. Overexpression of both genes were associated with adenocarcinoma of the lung. In accordance with overexpression of *CCND1* in our study group most recently Dragoj *et al.* [@B26] also reported overexpression of *CCND1* in the adenocarcinoma subtype. On the other hand, our results also support the data reported by Wilkerson *et al*. [@B32] who have observed *EMSY*overexpression in the stage 2 lung adenocarcinoma cell line.

We conclude that *EMSY* as a frequently amplified chromosome 11q13 region gene contributes to the progression of NSCLC in collaboration with *CCND1*. Therefore, the mechanism of the action of the *EMSY* gene in NSCLC warrants more detailed studies. Identifying its partners and investigation of the mutual interactions would help for the determination of new prognostic and predictive markers in NSCLC.
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###### 

Mean Ct values of EMSY and CCND1 genes compared to normalized values with G6PD gene in cancerous and non-cancerous tissue samples.

           EMSY Ct (Mean)        G6PD Ct (Mean)       ΔCt     ΔΔCt    2^-ΔΔCt^
  -------- --------------------- -------------------- ------- ------- ----------
  Tumor    28.97                 27.49                1.48    -0.71   1.64
  Normal   30.93                 28.74                2.19    \-      \-
           **CCND1 Ct (Mean)**   **G6PD Ct (Mean)**                   
  Tumor    26.31                 27.29                -0.98   -0.35   1.27
  Normal   29.12                 29.75                -0.63   \-      \-

###### 

Values of the patients showing concurrent pattern of either up- or down-regulation.

  ---------------------------------------------------------------
                         CCND                                 
  ----------- ---------- ----------- ------------ ----------- ---
                         Increase\   No-change\   Decrease\   p
                         n (%)       n (%)        n (%)       

  EMSY        Increase   45 (52.9)   3 (3.5)      8 (9.4)     

  No-change   1 (1.2)    1 (1.2)     0 (0)        \<0.001     

  Decrease    4 (4.7)    0 (0)       20 (23.5)                
  ---------------------------------------------------------------

###### 

Clinicopathologic characteristics of the patients and their distribution in relevance with EMSY and CCND1 expression.

                                CCND Expression   p           EMSY Expression                           
  --------------- ------------- ----------------- ----------- ----------------- ----------- ----------- -------
                  *Adeno Ca*    26 (52.0)         6 (26.1)    0.024             28 (50.0)   5 (25.0)    0.026
  **Histology**   *SCC*         17 (34.0)         17 (73.9)   20 (35.7)         15 (75.0)               
                  *n/a*         7 (14.0)          \-          8 (14.3)          \-                      
  **Stage**       *1-2A*        15 (57.7)         8 (66.7)    0.74              21 (60.0)   4 (66.7)    0.695
                  *2B-4*        11 (42.3)         4 (33.3)    14 (40.0)         2 (33.3)                
  **Sex**         *Male*        42 (85.7)         26 (92.8)   0.485             47 (85.4)   22 (95.6)   0.377
                  *Female*      7 (14.3)          2 (7.2)     8 (14.6)          1 (4.4)                 
  **Age**         *50 ≤ year*   9 (18.0)          3 (10.0)    0.432             10 (17.8)   2 (8.3)     0.456
                  *51 ≥ year*   41 (72.0)         27 (90.0)   46 (82.2)         22 (91.7)               
  **Tobacco**     *30 p/y*      23 (48.9)         14 (46.7)   0.233             26 (49.1)   12 (50.0)   0.101
                  *31-60 p/y*   22 (46.8)         12 (40.0)   25 (47.1)         10 (41.7)               
                  *\>60 p/y*    2 (4.3)           4 (13.3)    2 (3.8)           2 (8.3)                 
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